In this issue:
Adaptive nivo + ipi dosing based upon early CT in advanced melanoma
Immune, metabolic and genetic signatures predict response to anti–PD-1 in melanoma
Early readout on OS of patients with melanoma treated with ICI using a novel imaging analysis
Concordance of pathologic response between index LN and total LN bed after neoadjuvant ICI therapy in stage III melanoma
Characterisation of the treatment-naive immune microenvironment in melanoma with BRAF mutations
Dabrafenib, trametinib, + hydroxychloroquine in advanced BRAFV600-mutant melanoma
Dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600 mutant melanoma previously treated with BRAF-/MEK-inhibitors + ICIs
Efficacy and safety of angiogenesis inhibitors in melanoma
Prognostic value of β-blockers in trial of pembro vs placebo in resected high-risk stage III melanoma
Dermoscopic features and screening strategies for the detection of small-diameter melanomas
Please login below to download this issue (PDF)